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Objective
The aim of etanercept therapy in juvenile idiopathic
arthritis (JIA) is to achieve disease remission. However, lit-
tle is known about when or how to stop etanercept when
this aim is reached. Our objective was to describe charac-
teristics and disease course of JIA patients who discontin-
ued etanercept because of a sustained good clinical
response.
Methods
The "Arthritis and Biologicals in Children" (ABC)-project
is the Dutch national register on biologicals in JIA, in
which data are collected prospectively. All patients from
this register who discontinued etanercept because of a
good clinical response were selected. For evaluation of the
disease course we used the criteria for clinical remission
on medication and off medication by Wallace et al.
Results
Of the 210 patients in the ABC-register, 17 patients dis-
continued etanercept because of a good clinical response.
After discontinuation nine patients (53%), with a mean
follow-up of 1.4 years, did not develop a disease flare.
They showed a longer mean period of clinical remission
on medication (1.9 vs. 0.3 years, p  < 0.01) and used
etanercept longer (3.7 vs. 2.4 years, p = 0.16) compared to
patients who flared. Three out of the 17 patients discon-
tinued etanercept instantaneously and flared within one
year, all other patients tapered the etanercept dose before
discontinuation. All seven patients who resumed etaner-
cept use after flaring recovered soon.
Conclusion
Patients who meet the clinical remission criteria on
etanercept for a longer period have a better chance of
retaining remission after etanercept discontinuation.
Tapering of etanercept dose before discontinuation is
favourable.
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